[1] Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression [J]. Int J Radiat Biol, 2019, 95(7): 912-919.
[2] Abaffy T, Moller M G, Riemer D D, et al. Comparative analysis of volatile metabolomics signals from melanoma and benign skin: a pilot study [J]. Metabolomics, 2013, 9(5): 998-1008.
[3] Mun J H, Lee H, Yoon D, et al. Discrimination of basal cell carcinoma from normal skin tissue using high-resolution magic angle spinning 1H NMR spectroscopy [J]. PLoS One, 2016, 11(3): e0150328.
[4] Carichon M, Pallet N, Schmitt C, et al. Urinary metabolic finger print of acute intermittent porphyria analyzed by (1)H NMR spectroscopy [J].Anal Chem,2014, 86(4): 2166-2174.
[5] Assfalg M, Bortoletti E, D’Onofrio M, et al. An exploratory (1)H-nuclear magnetic resonance metabolomics study reveals altered urine spectral profiles in infants with atopic dermatitis [J]. Br J Dermatol, 2012, 166(5): 1123-1125.
[6] Smith C A, O’Maille G, Want E J, et al. METLIN: a metabolite mass spectral database [J]. Ther Drug Monit, 2005, 27(6): 747-751.
[7] Wishart D S, Feunang Y D, Marcu A. HMDB 4.0: the human metabolome database for 2018 [J]. Nucleic Acids Res, 2018, 46(D1): D608-D617.
[8] Xia J, Sinelnikov I V, Han B, et al. MetaboAnalyst 3.0--making metabolomics more meaningful [J]. Nucleic Acids Res, 2015, 43(W1): 251-257.
[9] Grapov D, Wanichthanarak K, Fiehn O. MetaMapR: pathway independent metabolomic network analysis incorporating unknowns [J]. Bioinformatics, 2015, 31(16): 2757-2760.
[10] Emwas A H,Luchinat C,Turano P,et al.Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review [J]. Metabolomics, 2015, 11( 4): 872-894.
[11] Banoei M M,Donnelly S J,Mickiewicz B,et al.Metabolomics in critical care medicine: a new approach to biomarker discovery [J]. Clin Invest Med, 2014, 37( 6): E363-E376.
[12] Kruk J,Doskocz M,Jod owska E,et al.NMR techniques in metabolomic studies: a quick overview on examples of utilization [J]. Appl Magn Reson, 2017, 48( 1): 1-21.
[13] Sato E,Kohno M,Yamamoto M,et al.Metabolomic analysis of human plasma from haemodialysis patients [J]. Eur J Clin Invest, 2011, 41( 3): 241.
[14] Dutkiewicz E P, Hsieh K T, Wang Y S,et al. Hydrogel micropatch and mass spectrometry-assisted screening for psoriasis related skin metabolites [J]. Clin Chem, 2016, 62(8): 1120-1128.
[15] Sitter B, Johnsson M K, Halgunset J,et al. Metabolic changes in psoriatic skin under topical corticosteroid treatment [J]. BMC Dermatol, 2013, 13: 8.
[16] Abeyakirthi S, Mowbray M, Bredenkamp N, et al. Arginase is overactivein psoriatic skin [J]. Br J Dermatol, 2010, 163(1): 193-196.
[17] Dennis E A, Norris P C. Eicosanoid storm in infection and inflammation [J]. Nat Rev Immunol, 2015, 15(8): 511-523.
[18] Wu N, Wang W, Yi M,et al. Study of the metabolomics characteristics of patients with metabolic syndrome based on liquid chromatography quadrupole time-of-flight mass spectrometry [J]. Ann Endocrinol (Paris), 2018, 79(1): 37-44.
[19] Fogh K. Lipoxygenase products of arachidonic acid in psoriasis, atopic dermatitis, and experimental arthritis [J]. Dan Med Bull, 1990, 37(4): 289-308.
[20] Armstrong A W, Wu J, Johnson M A, et al. Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis [J]. F1000Res, 2014, 3: 248.
[21] Kamleh M A, Snowden S G, Grapov D, et al. LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNF alpha treatment [J]. J Proteome Res, 2015, 14(1): 557-566.
[22] Kang H, Li X, Zhou Q, et al. Exploration of candidate biomarkers for human psoriasis based on GC-MS serum metabolomics [J]. Br J Dermatol, 2017, 176(3): 713-722.
[23] Ho J E, Larson M G, Ghorbani A, et al. Metabolomic profiles of body mass index in the framingham heart study reveal distinct cardiometabolic phenotypes [J]. PLoS One, 2016, 11(2): e0148361.
[24] Rebholz C M, Yu B, Zheng Z. Serum metabolomic profile of incident diabetes [J]. Diabetologia, 2018, 61(5): 1046-1054.
[25] Du F, Virtue A, Wang H,et al. Metabolomic analyses for atherosclerosis, diabetes, and obesity [J]. Biomark Res, 2013, 1(1): 17.
[26] LI L, Chuan J L, Ling H,et al. Untargeted serum metabonomics study of psoriasis vulgaris based on ultra-performance liquid chromatography coupled to mass spectrometry [J]. Oncotarget, 2017, 8(56): 95931-95944.
[27] Madsen R K, Lundstedt T, Gabrielsson J, et al. Diagnostic properties of metabolic perturbations in rheumatoid arthritis [J]. Arthritis Res Ther, 2011, 13(1): R19.
[28] Setkowicz M, Mastalerz L, Gielicz A, et al. Lack of association of ALOX12 and ALOX15B polymorphisms with psoriasis despite altered urinary excretion of 12(S)-hydroxyeicosatetraenoic acid [J]. Br J Dermatol, 2015, 172(2): 337-344.
[29] Alonso A, Julia A, Vinaixa M, et al. Urine metabolome profiling of immune-mediated inflammatory diseases [J]. BMC Mede, 2016, 14(1): 133.
[30] Kapoor S R, Filer A, Fitzpatrick M A, et al. Metabolic profiling predicts response to anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis [J]. Arthritis Rheum, 2013, 65(6): 1448-1456.